Today: 20 March 2026
Subscribe
Browse Category

NYSE:TME 12 November 2025

Tencent Music (TME) Q3 2025: Revenue +20.6% to RMB 8.46B, Profit +36%—Shares Slide ~10% After Earnings

Tencent Music (TME) Q3 2025: Revenue +20.6% to RMB 8.46B, Profit +36%—Shares Slide ~10% After Earnings

Tencent Music reported Q3 revenue of RMB 8.46 billion ($1.19 billion), up 20.6% year-on-year, with net profit to equity holders rising 36% to RMB 2.15 billion. Online-music paying users reached 125.7 million, up 5.6%, while monthly active users slipped 4.3% to 551 million. Shares fell about 10% intraday after an early gain, as investors focused on declining MAUs and social-entertainment revenue.
12 November 2025
···
Nasdaq Stumbles as Fed Jitters Mount, Intel Soars, Tariffs Rattle Tech Markets

US Stock Market Today, Nov. 12, 2025: Futures Climb as House Vote Aims to End Shutdown; CPI on Deck—What to Watch Before the Opening Bell

U.S. stock futures rose Wednesday as investors anticipated a House vote to end the 42-day federal shutdown, following Senate approval of a funding bill. The 10-year Treasury yield hovered near 4.09%. Oil and gold were steady. AMD jumped pre-market on strong AI guidance, while Nvidia sentiment was mixed after SoftBank’s stake sale.
12 November 2025
·········

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Go toTop